BridgeMD
Compares treatment options for Residual Neuromuscular Block
Official title Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
ClinicalTrials.gov ID: NCT07309393
What this study is testing
What is Sugammadex?
Sugammadex is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for residual neuromuscular block.
Also referred to as HengShu, Sugammadex sodium.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Residual neuromuscular blockade (NMB) after general anesthesia increases the risk of postoperative respiratory complications (atelectasis, pneumonia, re-intubation) and delays pulmonary function recovery. Sugammadex, a γ-cyclodextrin that directly encapsulates rocuronium, reverses NMB rapidly and completely without cholinergic side effects, whereas neostigmine requires co-administration of an antimuscarinic and may leave residual blockade.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Scheduled for elective unilateral thoracoscopic partial lung resection, with expected resection not exceeding one lung segment.
- Age between 18 and 80 years.
- American Society of Anesthesiologists (ASA) Physical Status classification I-III.
You likely can't join if
- Contraindications to drug use, such as history of allergy, epilepsy, angina, ventricular tachycardia; contraindicated in patients with mechanical...
- Inability to correctly cooperate with portable lung function testing.
- Hepatic or renal insufficiency.
- Pregnancy, lactation, potential for pregnancy, or planning pregnancy.
- Preoperative history of drug abuse or addiction.
- Second surgery during postoperative hospitalization.
See the full eligibility criteria
- Scheduled for elective unilateral thoracoscopic partial lung resection, with expected resection not exceeding one lung segment.
- Age between 18 and 80 years.
- American Society of Anesthesiologists (ASA) Physical Status classification I-III.
- Contraindications to drug use, such as history of allergy, epilepsy, angina, ventricular tachycardia; contraindicated in patients with mechanical intestinal obstruction or urinary tract obstruction; contraindicated in...
- Inability to correctly cooperate with portable lung function testing.
- Hepatic or renal insufficiency.
- Pregnancy, lactation, potential for pregnancy, or planning pregnancy.
- Preoperative history of drug abuse or addiction.
- Second surgery during postoperative hospitalization.
- Patients who refuse to participate.
- Other situations deemed inappropriate by the investigators shall be accompanied by a statement of the reasons.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.